Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is listed today as Actuate Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
7 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $5 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Feb 2024 | $3 M | No. 7 | $2 to $10 million | debt, options | SEC | |
| Sep 2022 | $19 M | No. 6 | $10 to $50 million | equity | SEC | |
| Nov 2020 | $14 M | No. 5 | $10 to $50 million | equity | SEC | |
| Oct 2019 | $7 M | No. 4 | $2 to $10 million | equity, options | SEC | |
| Apr 2019 | $22 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Aug 2018 | $4 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Mar 2017 | $3 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Actuate Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).
SEC Form D · Jul 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2025
That is all the official record says: Actuate Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Actuate Therapeutics, Inc. are on record.
Investors#
25 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bios Actuate Co-Invest III, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Actuate Co-Invest II, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Actuate Co-Invest I, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Advisors GP, LLC | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Capital Management, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Bios Clinical Opportunity Fund, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Bios Equity COF, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Equity Partners III, LP | Private equity | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Bios Equity Partners II, LP | Private equity | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Bios Equity Partners, LP | Private equity | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund III, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund III NT, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund III QP, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund II, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund II NT, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund II QP, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund I, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BIOS Fund I QP, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| BP Directors, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Cavu Advisors, LLC | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Cavu Management, LP | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2, B-3, B-4 and C preferred (Form 3, 2024) | SEC Form 3 |
| Kairos-Actuate SPV, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Kairos SPV Fund LLC | Fund or asset manager | not stated | not stated | Held Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Kairos Venture Opportunities I, L.P. | Venture capital | not stated | not stated | Held Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Kairos Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series B-1, B-2, B-3, B-4 and C preferred stock, director (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 95 investors.
Largest shareholders today
Institutions holding Actuate Therapeutics, Inc. shares, as of Sep 30, 2026.
- BIOS Capital Management, LP$8 M41.85%
- Voss Capital, LP$1 M7.91%
- Vanguard Capital Management LLC$0 M1.64%
- Geode Capital Management, LLC$0 M0.43%
- Texas Capital Bank Wealth Management Services Inc$0 M0.43%
- Palogic Value Management, L.P.$0 M0.42%
- Millennium Management LLC$0 M0.38%
- ABS Investment Management LLC$0 M0.30%
- BlackRock, Inc.$0 M0.28%
- Vanguard Fiduciary Trust Co$0 M0.23%
- Rock Creek Group LLC$0 M0.21%
- Sfmg, LLC$0 M0.21%
- HighTower Advisors, LLC$0 M0.15%
- Susquehanna International Group, LLP$0 M0.10%
- Bridgeway Capital Management, LLC$0 M0.10%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew G.L. Mazar | Executive officer | Jul 2025 |
| Daniel Schmitt | Executive officer | Jul 2025 |
| Paul Lytle | Executive officer | Jul 2025 |
| Daniel M. Schmitt | Executive officer | Nov 2019 |
| Daniel M Schmitt | Executive officer | May 2019 |
| Aaron G.L. Fletcher | Director | Jul 2025 |
| Amy G.L. Ronneberg | Director | Jul 2025 |
| Daniel G.L. Zabrowski | Director | Jul 2025 |
| Daniel Schmitt | Director | Jul 2025 |
| Jason G.L. Keyes | Director | Jul 2025 |
| Roger G.L. Sawhney | Director | Jul 2025 |
| Todd G.L. Thomson | Director | Jul 2025 |
| Aaron Fletcher | Director | Mar 2024 |
| Dan Zabrowski | Director | Mar 2024 |
| Leslie Kreis, Jr. | Director | Mar 2024 |
| Todd Thomson | Director | Mar 2024 |
| Aaron Glenn Louis Fletcher | Director | Dec 2022 |
| Dan Wayne Zabrowski | Director | Dec 2022 |
| Leslie Wayne Kreis, Jr. | Director | Dec 2022 |
| Todd Wayne Thomson | Director | Dec 2022 |
| Alex Wayne Andrianopoulos | Director | Dec 2020 |
| Pascal Wayne Krotee | Director | Dec 2020 |
| Daniel M. Schmitt | Director | Nov 2019 |
| Neil Wayne Bajpayee | Director | Nov 2019 |
| Daniel M Schmitt | Director | May 2019 |
| Leslie Wayne Kreis Jr. | Director | May 2019 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.